Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA
Zacks Investment Research | Dec 02, 2020 06:03AM ET
Acceleron Pharma (NASDAQ:XLRN) Inc. industry ’s growth of 4.3%.
Notably, an orphan drug designation is usually granted to drugs that are capable of treating rare diseases that affect less than 200,000 people in the United States. This tag also makes the company entitled to certain other benefits, including tax credits related to clinical trial expenses and an exemption from the FDA user fee.
ACE-1334 is a transforming growth factor (TGF)-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands, which are believed to be key signaling factors in the pathogenesis of the fibrotic disease.
In preclinical studies, ACE-1334 has been observed to have antifibrotic activity in multiple models of fibrosis. The investigational drug was recently evaluated in an ascending-dose phase I study in healthy volunteers. The company intends to initiate a phase Ib/phase II study in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in 2021. The company intends to initiate the study to determine whether the anti-fibrotic activity ACE-1334 has demonstrated in preclinical models of fibrosis can be replicated in patients with SSc-ILD.
Apart from ACE-1334, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH). The company reported positive top-line results from the PULSAR phase II study. It is currently planning multiple phase III studies to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease.
The company’s drug Reblozyl is a novel erythroid maturation agent (EMA) approved to treat anaemia associated with beta-thalassemia in adult patients who require regular red blood cell (RBC) transfusions.
Zacks Rank & Stocks to Consider
Acceleron currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include ASLAN Pharmaceuticals Ltd. .
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days.
Aptose’s loss per share estimates have narrowed from 77 cents to 69 cents for 2020 and from 85 cents to 81 cents for 2021 over the past 60 days.
Alimera’s loss per share estimates have narrowed from $1.31 to 96 cents for 2020 over the past 60 days.
Get The News You Want
Acceleron Pharma Inc. Quote
h3 Zacks Names “Single Best Pick to Double” /h3
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research SherazMian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it’s poised for a monster turnaround.
Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer (NYSE:SAM) Company which shot up +143.0% in a little more than 9 months and Nvidia (NASDAQ:NVDA) which boomed +175.9% in one year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.